Evaluating the Association Between Vasopressin Use and In-Hospital Mortality in Patients with Septic Shock

Michael Pasqualicchio  
*Baptist Hospital of Miami*, MichaelPa@baptisthealth.net

Heidi Clarke  
*Baptist Hospital of Miami*, heidic@baptisthealth.net

Jonathan Kline  
*Baptist Hospital of Miami*, JonathanDK@baptisthealth.net

Payal Patel  
*Baptist Hospital of Miami*, PayalDP@baptisthealth.net

Follow this and additional works at: [https://scholarlycommons.baptisthealth.net/se-all-publications](https://scholarlycommons.baptisthealth.net/se-all-publications)

Part of the Chemicals and Drugs Commons, Critical Care Commons, and the Pharmacy and Pharmaceutical Sciences Commons

Citation

Pasqualicchio, Michael; Clarke, Heidi; Kline, Jonathan; and Patel, Payal, "Evaluating the Association Between Vasopressin Use and In-Hospital Mortality in Patients with Septic Shock" (2020). *All Publications*. 3535.  
[https://scholarlycommons.baptisthealth.net/se-all-publications/3535](https://scholarlycommons.baptisthealth.net/se-all-publications/3535)

This Conference Lecture -- Open Access is brought to you for free and open access by Scholarly Commons @ Baptist Health South Florida. It has been accepted for inclusion in All Publications by an authorized administrator of Scholarly Commons @ Baptist Health South Florida. For more information, please contact Carrief@baptisthealth.net.
Evaluating the association between vasopressin use and in-hospital mortality in patients with septic shock

Michael Pasqualicchio, PharmD, BCPS
PGY-2 Critical Care Pharmacy Resident
Baptist Hospital of Miami
Michaelpa@baptisthealth.net
Disclosure statement

The following contributors have nothing to disclose regarding any financial or nonfinancial relationships with the products described, reviewed, or evaluated in this presentation:

- Michael Pasqualicchio, PharmD, BCPS
- Heidi Clarke, PharmD, BCCCP
- Jonathan Kline, PharmD, BCCCP
- Payal Patel, PharmD, BCCCP
Evaluate the mortality associated with adding vasopressin to both low-dose and high-dose vasopressors in patients with septic shock
Sepsis

- Uncontrolled, generalized, intravascular inflammatory response to infection
- Most common cause of death in intensive care units (ICUs)\(^1\)
  - Increasing incidence over the last 10 years
  - In-hospital mortality rate of greater than 40\(^2\)
  - Most expensive condition to treat in 2013: $24 billion in annual costs\(^3\)

- Treatment:
  - Fluid resuscitation (30 ml/kg)
  - Prompt administration of broad-spectrum antimicrobial agents
  - Vasoactive medications
Surviving Sepsis Guidelines

- Norepinephrine recommended as first-choice vasopressor (strong recommendation, moderate quality of evidence)
- Suggest adding either vasopressin (weak recommendation, low quality of evidence) or epinephrine (weak recommendation, low quality of evidence)
  - Raise MAP to target (recommended target of 65 mmHg)
  - Decrease norepinephrine requirements
Vasopressin mechanism

- Distinct mechanism compared to catecholamine agents
- Activates V1 receptors
  - Induces constriction of vascular smooth muscle cells through increased intra-cellular calcium and decreased nitric oxide induced vasodilation
- Endogenous levels initially increase in response to hypotension but quickly decline within 36 hours
- Maintains efficacy in acidotic state
VASST trial

- Multi-center, randomized, double-blind trial
- Patients receiving norepinephrine at a minimum rate of 5 mcg/minute were randomly divided into two groups:
  - Low-dose vasopressin (in addition to open-label vasopressors)
  - Norepinephrine (in addition to open-label vasopressors)
- Primary outcome: 28-day mortality after the initiation of study infusion
- Sub-group analysis that divided patients into additional two groups:
  - Less severe shock: Norepinephrine rate 5-14 mcg/minute at randomization
  - More severe shock : Norepinephrine rate ≥15 mcg/minute at randomization
## VASST trial results

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Norepinephrine (n=382)</th>
<th>Vasopressin (n=396)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Time to study drug infusion - hours</strong></td>
<td>11.5 ± 9.4</td>
<td>11.9 ± 8.9</td>
<td>0.57</td>
</tr>
<tr>
<td>28-day mortality – no (%)</td>
<td>150 (39.3)</td>
<td>140 (35.4)</td>
<td>0.26</td>
</tr>
<tr>
<td>90-day mortality – no (%)</td>
<td>188 (49.6)</td>
<td>172 (43.9)</td>
<td>0.11</td>
</tr>
<tr>
<td><strong>More severe shock – NE ≥ 15 mcg/minute</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>28-day mortality – no/total no (%)</td>
<td>85/200 (42.5)</td>
<td>88/200 (44.0)</td>
<td>0.76</td>
</tr>
<tr>
<td>90-day mortality – no/total no (%)</td>
<td>105/199 (52.8)</td>
<td>103/199 (51.8)</td>
<td>0.84</td>
</tr>
<tr>
<td><strong>Less severe shock – NE 5-14 mcg/minute</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>28-day mortality – no/total no (%)</td>
<td>65/182 (35.7)</td>
<td>52/196 (26.5)</td>
<td>0.05</td>
</tr>
<tr>
<td>90-day mortality – no/total no (%)</td>
<td>83/180 (46.1)</td>
<td>69/193 (35.8)</td>
<td>0.04</td>
</tr>
</tbody>
</table>
VANISH trial

- Factorial, double-blind, randomized trial
- Four groups:
  - Vasopressin and hydrocortisone
  - Vasopressin and placebo
  - Norepinephrine and hydrocortisone
  - Norepinephrine and placebo
- Primary outcome: Kidney failure-free days 28-days post randomization
## VANISH trial results

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Vasopressin + hydrocortisone (n=100)</th>
<th>Vasopressin + placebo (n=104)</th>
<th>Norepinephrine + hydrocortisone (n=101)</th>
<th>Norepinephrine + placebo (n=103)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Time to study drug infusion - hours</strong></td>
<td>3.2 (1.8-5)</td>
<td>3.5 (2.5-5.4)</td>
<td>3.7 (1.7-5)</td>
<td>3.5 (1.4-5.4)</td>
</tr>
<tr>
<td><strong>28-day mortality – no/total no (%)</strong></td>
<td>33/100 (33.0)</td>
<td>30/104 (28.8)</td>
<td>29/101 (28.7)</td>
<td>27/103 (26.2)</td>
</tr>
<tr>
<td><strong>ICU mortality – no/total no (%)</strong></td>
<td>32/100 (32.0)</td>
<td>26/104 (25.0)</td>
<td>24/101 (23.8)</td>
<td>27/103 (26.2)</td>
</tr>
<tr>
<td><strong>Hospital mortality – no/total no (%)</strong></td>
<td>35/100 (35.0)</td>
<td>33/104 (31.7)</td>
<td>31/101 (30.7)</td>
<td>29/103 (28.2)</td>
</tr>
<tr>
<td><strong>Time to shock reversal - hours</strong></td>
<td>50 (28-92)</td>
<td>59 (27-112)</td>
<td>46 (23-72)</td>
<td>44 (23-90)</td>
</tr>
</tbody>
</table>
### Additional studies

<table>
<thead>
<tr>
<th>Trial</th>
<th>Comparison</th>
<th>Outcomes</th>
</tr>
</thead>
</table>
| **Reardon et al.**<sup>9</sup>  
Single-center, retrospective, chart-review  
N=71  
**Vasopressin initiation within 6 hours of shock onset vs. vasopressin within 6-48 hours of shock onset** | ▪ Early vasopressin resulted in significantly less new-onset arrhythmias  
▪ No difference in duration of catecholamine and vasopressin therapy  
▪ No difference in mortality or ICU/hospital length of stay |                                                                                                                                        |
| **Hammond et al.**<sup>10</sup>  
Single-center, prospective, open-label study  
N=82  
**Early addition of vasopressin within 4 hours of septic shock onset vs. norepinephrine monotherapy** | ▪ Significantly shorter time to MAP target (7.6 vs. 5.7 hours; p=0.058)  
▪ No difference in mortality, norepinephrine duration, vasopressin duration, or ICU/hospital length of stay |                                                                                                                                        |
| **Hammond et al.**<sup>11</sup>  
Single-center, retrospective, cohort study  
N=96  
**Early addition of vasopressin within 4 hours of septic shock onset vs. norepinephrine monotherapy** | ▪ Significantly shorter time to MAP target and hospital length of stay but no difference in ICU length of stay  
▪ Significantly greater reduction in SOFA score at 72 hours post shock onset  
▪ No difference in SOFA score at 6, 24, or 72 hours post shock onset  
▪ No difference in in-hospital or 28-day mortality  
▪ No difference in norepinephrine duration |                                                                                                                                        |
| **Wu et al.**<sup>12</sup>  
Single-center, retrospective, cohort study  
N=148  
**Vasopressin initiation for patients requiring ≥10 mcg/min of norepinephrine vs. patients requiring ≥50 mcg/min of norepinephrine** | ▪ No difference in time to MAP target, mortality, or ICU/hospital length of stay |                                                                                                                                        |
Study rationale

Conflicting evidence and lack of recommendations regarding:

- Optimal candidates for vasopressin
- Optimal timing of vasopressin initiation
- Optimal timing of vasopressin discontinuation

High relative cost of vasopressin compared to other vasopressors prioritizes its optimization
Purpose

To evaluate outcomes for patients with septic shock based on the utilization of vasopressin

Research questions:

- Does the addition of vasopressin to low-dose vasopressors in patients with septic shock reduce in-hospital mortality?
- Does the addition of vasopressin to high-dose vasopressors in patients with septic shock reduce in-hospital mortality?
Design

**Design:** IRB-exempt, retrospective chart review of patients treated with vasopressors and diagnosed with septic shock

**Time frame:** January 1, 2018 to September 17, 2018

**Setting:** Intensive care unit (ICU) at Baptist Hospital of Miami

**Sample size:** 149 patients
Subject selection

Inclusion criteria

• ≥ 18 years old
• “Septic shock” documented in the medical record
• Vasopressor infusion

Exclusion criteria

• Pregnant
• “Cardiogenic shock” documented in the medical record
• Post-cardiothoracic surgery
• <12 hours on vasopressors
## Comparator groups

<table>
<thead>
<tr>
<th>Low-dose vasopressors:</th>
<th>≤ 0.2 mcg/kg/minute NE equivalents</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Patients treated with vasopressin</td>
<td></td>
</tr>
<tr>
<td>• Patients treated without vasopressin</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>High-dose vasopressors:</th>
<th>&gt; 0.2 mcg/kg/minute NE equivalents</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Patients treated with vasopressin</td>
<td></td>
</tr>
<tr>
<td>• Patients treated without vasopressin</td>
<td></td>
</tr>
</tbody>
</table>
Study outcomes

Primary outcome:
- In-hospital mortality from any cause or initiation of hospice care

Secondary outcomes:
- Total time on vasopressors (hours)
- Number of catecholamine agents required
- ICU length of stay (days)
- Hospital length of stay (days)
Subject selection

Initial review
n=998

Included
n=149

Excluded (n=849)
- <18 years old
- <12 hours on vasopressors
- No septic shock diagnosis
- Post-cardiothoracic surgery
- Cardiogenic shock diagnosis
- No vasopressors initiated

Septic shock accounted for ~38% of vasopressin utilization over this time period

Low-dose vasopressor arm
n=55

High-dose vasopressor arm
n=94

No vasopressin
n=35

Vasopressin
n=20

No vasopressin
n=46

Vasopressin
n=48
Results: Low-dose arm
## Baseline characteristics: Low-dose arm

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>No vasopressin (n=35)</th>
<th>Vasopressin (n=20)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age - years</td>
<td>70.7 ± 13.7</td>
<td>63.7 ± 18.7</td>
<td>0.12</td>
</tr>
<tr>
<td>Male sex – no (%)</td>
<td>23 (65.7)</td>
<td>11 (55)</td>
<td>0.43</td>
</tr>
<tr>
<td>APACHE II score</td>
<td>18.1 ± 5.8</td>
<td>18.1 ± 7.0</td>
<td>1.00</td>
</tr>
<tr>
<td>SOFA score</td>
<td>5.1 ± 2.2</td>
<td>5.6 ± 2.6</td>
<td>0.45</td>
</tr>
<tr>
<td>Lactic acid – mg/dL</td>
<td>3.0 ± 1.9</td>
<td>3.2 ± 2.6</td>
<td>0.74</td>
</tr>
<tr>
<td>MAP – mmHg</td>
<td>65.3 ± 12.0</td>
<td>63.7 ± 8.8</td>
<td>0.60</td>
</tr>
<tr>
<td>NE-equivalent dose – mcg/kg/min</td>
<td>10.4 ± 5.4</td>
<td>10.6 ± 7.8</td>
<td>0.91</td>
</tr>
</tbody>
</table>

All baseline characteristics at time of vasopressor initiation  
All values displayed as mean ± standard deviation unless otherwise noted  
NE-equivalent dose equation from VASST trial  
NE-equivalent = Norepinephrine + Epinephrine + (Dopamine/2) + (Phenylephrine/10)
# Outcomes: Low-dose arm

<table>
<thead>
<tr>
<th></th>
<th>No vasopressin (n=35)</th>
<th>Vasopressin (n=20)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>In-hospital mortality – no (%)</td>
<td>7 (20.0)</td>
<td>7 (35.0)</td>
<td>0.22</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Secondary outcomes</strong></th>
<th>No vasopressin (n=35)</th>
<th>Vasopressin (n=20)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean time on vasopressors - hours</td>
<td>52.6 ± 56.3</td>
<td>75.5 ± 40.2</td>
<td>0.12</td>
</tr>
<tr>
<td>Mean time on vasopressors for patients surviving to discharge - hours</td>
<td>45.3 ± 38.4</td>
<td>66.9 ± 41.2</td>
<td>0.06</td>
</tr>
<tr>
<td>Mean ICU length of stay - days</td>
<td>3.6 ± 2.8</td>
<td>10.1 ± 9.0</td>
<td>0.0002</td>
</tr>
<tr>
<td>Mean hospital length of stay - days</td>
<td>12.8 ± 12.5</td>
<td>30.6 ± 27.4</td>
<td>0.001</td>
</tr>
<tr>
<td>Number of catecholamines at time of inclusion</td>
<td>One agent: 35 (100)</td>
<td>No other agents: 4 (20) One agent: 14 (70) Two agents: 2 (10)</td>
<td></td>
</tr>
<tr>
<td>Maximum number of catecholamines following inclusion</td>
<td>One agent: 34 (97) Two agents: 1 (3)</td>
<td>One agent: 10 (50) Two agents: 9 (45) Three agents: 1 (5)</td>
<td></td>
</tr>
</tbody>
</table>
## Additional data: Low-dose arm

<table>
<thead>
<tr>
<th></th>
<th>No vasopressin (n=35)</th>
<th>Vasopressin (n=20)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steroids administered – no (%)</td>
<td>17 (49)</td>
<td>9 (45)</td>
</tr>
<tr>
<td>Midodrine administered – no (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Average norepinephrine rate of 2.6 mcg/min at initiation</td>
<td>9 (26)</td>
<td>2 (10)</td>
</tr>
<tr>
<td>Mean time to vasopressin administration - hours (range)</td>
<td></td>
<td>10.8 (0-45.3)</td>
</tr>
<tr>
<td>Mean duration of vasopressin – hours (range)</td>
<td></td>
<td>40.7 (12.3-90.8)</td>
</tr>
</tbody>
</table>
Results: High-dose arm
### Baseline characteristics: High-dose arm

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>No vasopressin (n=46)</th>
<th>Vasopressin (n=48)</th>
<th>$p$-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age - years (years)</td>
<td>75.8 ± 10.8</td>
<td>73.2 ± 14.2</td>
<td>0.18</td>
</tr>
<tr>
<td>Male sex – no (%)</td>
<td>32 (69.6)</td>
<td>27 (56.3)</td>
<td>0.16</td>
</tr>
<tr>
<td>APACHE II score</td>
<td>21.2 ± 6.0</td>
<td>22.6 ± 6.5</td>
<td>0.28</td>
</tr>
<tr>
<td>SOFA score</td>
<td>6.0 ± 2.3</td>
<td>6.5 ± 3.1</td>
<td>0.38</td>
</tr>
<tr>
<td>Lactic acid – mg/dL</td>
<td>3.1 ± 1.9</td>
<td>4.7 ± 4.6</td>
<td>0.03</td>
</tr>
<tr>
<td>MAP – mmHg</td>
<td>67.1 ± 15.5</td>
<td>66.8 ± 15.3</td>
<td>0.93</td>
</tr>
<tr>
<td>NE-equivalent dose – mcg/kg/min</td>
<td>42.4 ± 49.2</td>
<td>58.2 ± 53.3</td>
<td>0.14</td>
</tr>
</tbody>
</table>

All baseline characteristics at time of vasopressor initiation

All values displayed as mean ± standard deviation unless otherwise noted

NE-equivalent dose equation from VASST trial

NE-equivalent = Norepinephrine + Epinephrine + (Dopamine/2) + (Phenylephrine/10)
## Outcomes: High-dose arm

<table>
<thead>
<tr>
<th></th>
<th>No vasopressin (n=46)</th>
<th>Vasopressin (n=48)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>In-hospital mortality – no (%)</td>
<td>20 (43.5)</td>
<td>34 (70.8)</td>
<td>0.007</td>
</tr>
</tbody>
</table>

### Secondary outcomes

<table>
<thead>
<tr>
<th></th>
<th>No vasopressin (n=46)</th>
<th>Vasopressin (n=48)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean time on vasopressors - hours</td>
<td>95.4 ± 86.8 (Median: 74.2)</td>
<td>171.7 ± 211.2 (Median: 76.5)</td>
<td></td>
</tr>
<tr>
<td>Mean time on vasopressors for patients surviving to discharge - hours</td>
<td>81.9 ± 71.8 (Median: 70.6)</td>
<td>141.6 ± 142.1 (Median: 70.5)</td>
<td></td>
</tr>
<tr>
<td>Mean ICU length of stay - days</td>
<td>7.3 ± 6.8 (Median: 5.0)</td>
<td>9.4 ± 15.2 (Median: 5.0)</td>
<td>0.39</td>
</tr>
<tr>
<td>Mean hospital length of stay - days</td>
<td>17.5 ± 12.0 (Median: 14.0)</td>
<td>16.1 ± 16.6 (Median: 12.0)</td>
<td>0.64</td>
</tr>
<tr>
<td>Number of catecholamines at time of inclusion</td>
<td>One agent: 35 (76) One agent: 35 (73)</td>
<td>Two agents: 11 (24) Two agents: 13 (27)</td>
<td></td>
</tr>
</tbody>
</table>
## Additional data: High-dose arm

<table>
<thead>
<tr>
<th></th>
<th>No vasopressin (n=46)</th>
<th>Vasopressin (n=48)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steroids administered – no (%)</td>
<td>21 (45.7)</td>
<td>25 (52.1)</td>
</tr>
<tr>
<td>Midodrine administered – no (%)</td>
<td>20 (43.5)</td>
<td>19 (39.6)</td>
</tr>
<tr>
<td>Mean time to vasopressin administration - hours (range)</td>
<td></td>
<td>24.7 (0-177.3)</td>
</tr>
<tr>
<td>Mean duration of vasopressin – hours (range)</td>
<td></td>
<td>62.4 (1.8-403)</td>
</tr>
</tbody>
</table>
Limitations

- Higher vasopressin dose utilized than recommended by the Surviving Sepsis Guidelines
- Small sample size in low-dose vasopressor with vasopressin group (n=20)
- Potential for inaccurate charting of vasopressor initiation, rate change, and discontinuation
- Potential for inaccurate reporting of septic shock diagnosis in electronic medical record
- Unknown administration of fluid resuscitation prior to initiation of vasopressors
- Additional causes of mortality not accounted for
- Evaluated in-hospital mortality with unknown extended outcomes
Conclusions

- No in-hospital mortality benefit associated with vasopressin utilization in both the low- and high-dose arms
- No difference in duration of vasopressor therapy associated with vasopressin administration in both the low- and high-dose arms
- Opportunity for optimization of vasopressin utilization based on poor associated outcomes
Self-assessment question

Which of the following is an outcome of the VASST trial?

A. 28-day mortality benefit seen with initiation of vasopressin prior to norepinephrine
B. Increased 28-day mortality for patients administered vasopressin
C. Significantly more days free of organ dysfunction for patients administered vasopressin
D. 90-day mortality benefit for patients with less-severe septic shock administered vasopressin
Self-assessment answer

Which of the following is an outcome of the VASST trial?

A. 28-day mortality benefit seen with initiation of vasopressin prior to norepinephrine
B. Increased 28-day mortality for patients administered vasopressin
C. Significantly more days free of organ dysfunction for patients administered vasopressin
D. 90-day mortality benefit for patients with less-severe septic shock administered vasopressin
References

Acknowledgements

- Heidi Clarke, PharmD, BCCCP
- Jonathan Kline, PharmD, BCCCP
- Payal Patel, PharmD, BCCCP
Evaluating the association between vasopressin use and in-hospital mortality in patients with septic shock

Michael Pasqualicchio, PharmD, BCPS
PGY-2 Critical Care Pharmacy Resident
Baptist Hospital of Miami
Michaelpa@baptisthealth.net